Clinical Validation of the Cervista HPV HR Test According to the International Guidelines for Human Papillomavirus Test Requirements for Cervical Cancer Screening

Aniek Boers, Rong Wang, Lorian Slagter-Menkema, Bettien M. van Hemel, Hilde Ghyssaert, Ate G. J. van der Zee, G. Bea A. Schuurs-Wisman, Ed Schuuring*

*Bijbehorende auteur voor dit werk

OnderzoeksoutputAcademicpeer review

18 Citaten (Scopus)
333 Downloads (Pure)

Samenvatting

This study demonstrates that both the clinical sensitivity and specificity of the Cervista HPV HR test for high-risk human papillomavirus (HPV) detection are not inferior to those of the Hybrid Capture 2 (HC2) test. The intra- and interlaboratory reproducibilities of Cervista were 92.0% (kappa, 0.83) and 90.4% (kappa, 0.80), respectively. The Cervista HPV HR test fulfills all the international HPV test requirements for cervical primary screening purposes.

Originele taal-2English
Pagina's (van-tot)4391-4393
Aantal pagina's3
TijdschriftJournal of Clinical Microbiology
Volume52
Nummer van het tijdschrift12
DOI's
StatusPublished - dec.-2014

Citeer dit